Novanta Reports Mixed 2025 Results: Revenue Up but Profits Pressured…

Event summary

Novanta reported Q4 2025 revenue of $258.3M, up 9% YoY, with full-year revenue at $980.6M (+3.3%).
GAAP net income fell to $17.5M in Q4 (-6.1% YoY) and $53.8M for the year (-16.2% YoY).
Adjusted EBITDA rose 17% QoQ to $60.7M, with full-year adjusted EPS up 6.8% to $3.29.
Customer bookings surged 25% in Q4, with a book-to-bill ratio of 1.11x.
Company guides for mid-single-digit organic growth in 2026, targeting $1.03B-$1.05B revenue.

The big picture

Novanta's mixed 2025 results reflect the tension between revenue growth from acquisitions and organic challenges, particularly in medical solutions. The company's focus on strategic acquisitions and operational efficiency aligns with broader industry trends toward regionalized manufacturing and cost optimization. With a strong backlog and aggressive guidance for 2026, Novanta aims to position itself as a resilient player in the competitive medical and advanced industrial technology sectors.

What we're watching

Execution Risk: Whether Novanta can sustain its bookings momentum and convert it into revenue growth amid regional manufacturing transitions.
Strategic Growth: The pace at which the company deploys capital through acquisitions to drive shareholder value, given its largest-ever acquisition pipeline.
Operational Efficiency: How successfully Novanta completes its regional manufacturing strategy and improves margins in 2026.